You Had Me at “Hello” The Remarkable Growth of Upfront Payments in Biopharma Alliances
Evolving Deal Terms
Recent Trends in Effective Royalty Rates of Biopharma Alliances
Alliance Trends
Biopharma Milestone Payments Negotiating an Equitable Value Allocation
Evolving Deal Terms
Immuno-Oncology Alliances Command Big Deal Premiums
Alliance Trends
Recent Trends & How Far You Can Go
Evolving Deal Terms
Sharing the Wealth Recent Trends in Biopharma Sublicensing
Evolving Deal Terms
The Best Biotech IPO Window ...That Money Can Buy!
Biofinancing
Changing the Deal How Far Can You Go & How Often
Alliance Trends
Dawn of a Post-Venture Era: The New Face of Innovation & Translational Research
Biofinancing
Effective Royalty Rates in Biopharma Alliances What They Are and Why Use Them in Negotiations
Evolving Deal Terms
Yours, Mine & Ours Partnering Compounds Globally
Alliance Trends
Top Pharma Vs. Major Biotech Who is Biopharma’s Favorite Alliance Partner?
Evolving Deal Terms
Orphan Drug Alliances
Alliance Trends
Co-Promotion in Biopharma Agreements Success is in the Details
Evolving Deal Terms
Trends in University Licenses How Healthy is the Seed Corn?
Alliance Trends
The BioPharma Industry in 2015 As Good as it Gets
Biofinancing
Duration of Royalty Obligations ’Til Death Do Us Part?
Alliance Trends
Re‐emergence of Platform Technologies Gonna Party Like It’s 1999
Evolving Deal Terms
2014 Year in Review IPOs, Financings & Alliances
Biofinancing
Sales Milestones Bridging the Valuation Gap
Alliance Trends
Demand Dividend A New Investment Vehicle for Financing Biotech Companies
Biofinancing
Biotech IPOs Springboard for Success
Biofinancing
Biotech Sell Side Research A Retrospective Analysis
Sell-Side Analysis